Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis

N/ACompletedNCT02008266

Hoffmann-La Roche532 enrolled

Overview

This non-interventional, descriptive, cross-sectional and multicenter study will examine the treatment of rheumatoid arthritis progressing for less than two years in the Algerian population. Current drug therapy as well as disease status and patient function will be assessed.

Study Type

OBSERVATIONAL

Enrollment

532

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Rheumatoid arthritis progressing for \< 2 years. Exclusion Criteria: * Rheumatoid arthritis progressing for \< 3 months. * Rheumatoid arthritis onset at \< 18 years of age. * Participation in another clinical study. * Rheumatoid arthritis related connective tissue disorder. * Any neuropsychological disorders.

Outcomes

Primary Outcomes

Describe medications used in the treatment of rheumatoid arthritis with < 2 years' progression.

Time frame: Single observational visit [Day 1]

Secondary Outcomes

Measure disease activity using DAS 28 assessment.

Time frame: Single observational visit [Day 1]

Assess joint damage using the modified SHARP method.

Time frame: Single observational visit [Day 1]

Assess functional status of patients using the Health Assessment Questionnaire (HAQ).

Time frame: Single observational visit [Day 1]

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.